Proceedings of the Tenth International Conference of Drug Regulatory Authorities (ICDRA) - Hong Kong, China, 24 - 27 June 2002
(2002; 166 pages) View the PDF document
Table of Contents
View the documentAbbreviations and acronyms used in this report
Open this folder and view contentsOpening ceremony
Open this folder and view contentsHerbal medicines
Open this folder and view contentsKeynote address
Open this folder and view contentsSafety of blood-derived products
Open this folder and view contentsAntimicrobial resistance - new initiatives
Open this folder and view contentsHarmonization I
Open this folder and view contentsHarmonization II
Open this folder and view contentsProtection of trial subjects in clinical trials
Open this folder and view contentsRegulating biotechnology products
Open this folder and view contentsRegulatory challenges: health sector reform and drug regulatory capacity
Open this folder and view contentsAccess to drugs and vaccines I
Open this folder and view contentsAccess to drugs and vaccines II
Close this folderCounterfeit pharmaceutical products
View the documentCounterfeit pharmaceutical products
View the documentThe fight against counterfeit drugs in the Russian Federation
View the documentCounterfeit medicines
View the documentRecommendations
Open this folder and view contentsHomoeopathy
Open this folder and view contentsSafety monitoring
Open this folder and view contentsE-Commerce
Open this folder and view contentsCurrent topics
Open this folder and view contentsRegulatory challenges of new technologies
View the documentList of participants
View the documentBack cover
 

Recommendations

1. Governments should acknowledge the problem of counterfeit drugs by developing national policies and providing a comprehensive legal framework to regulate trading of counterfeit drugs as a criminal offence.

2. Governments should adopt WHO guidelines for the development of measures to combat counterfeit drugs.

3. Governments of exporting countries should have a system of control to prevent the export of counterfeit drugs.

4. Drug regulatory authorities should establish a working relationship with national (police, customs) and international (Interpol, World Customs Organization) law enforcement agencies.

5. Drug regulatory authorities should establish an effective registration system to include the licensing of manufacturers, wholesalers, and retail outlets.

6. Drug regulatory authorities should seek to cooperate with the drug industry in the exchange of information on counterfeit drugs, and to promote reporting of counterfeit drugs to WHO.

7. WHO should strengthen the existing anti-counterfeit liaison officers to promote exchange of information on counterfeit drugs amongst and between regulatory authorities and WHO.

8. WHO should encourage and support Member States to develop and implement national measures for combating counterfeit drugs.

9. WHO should organize meetings to enhance international communication on counterfeit problems and encourage and assist regulatory authorities in the delivery of public awareness programmes on the dangers of counterfeit drugs.

10. Progress should be reported back to the ICDRA.

 

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: March 20, 2014